Tarsus Pharmaceuticals, Inc. (TARS) Stock Price & Analysis
Tarsus Pharmaceuticals, Inc. (TARS) rose 9.10% to USD 90.78 as of September 8, 2026 at 06:21 UTC, according to Nexqual real-time market data.
TARS last closed at USD 83.21; the session ranged USD 81.07–91.53 on volume of 1,595,936 shares. Market capitalization is $3.98B, with a 52-week range of USD 48.2–91.53 (NMS). Source: Nexqual, September 8, 2026 at 06:21 UTC.
Key Statistics (as of September 8, 2026 at 06:21 UTC)
| Price | USD 90.78 |
|---|---|
| Change | ▲ 9.10% (up) |
| Previous Close | USD 83.21 |
| Open | USD 82.71 |
| Day Range | USD 81.07 – 91.53 |
| 52-Week Range | USD 48.2 – 91.53 |
| Volume | 1,595,936 shares |
| Market Cap | $3.98B |
| Exchange | NMS |
Technical Analysis (TARS)
Nexqual's technical model rates TARS "BUY" based on 5 bullish and 3 bearish signals across 128 daily candles, as of September 8, 2026 at 06:21 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 87.78 (overbought) |
| vs SMA50 | Above (USD 65.96) |
| MACD | 4.96 (positive) |
Analyst Ratings (TARS)
Wall Street analysts rate TARS "Strong Buy" based on 8 analysts, with a mean price target of USD 94 (range USD 84–104), per Nexqual as of September 8, 2026 at 06:21 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 94 |
| High Target | USD 104 |
| Low Target | USD 84 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (TARS)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD -1.53 |
| Revenue Estimate | $180.75M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.43 vs est -0.2 ▼ miss |
| 2026-03-31 | USD -0.16 vs est -0.42 ▲ beat |
| 2025-12-31 | USD -0.2 vs est 0.01 ▼ miss |
| 2025-09-30 | USD -0.3 vs est -0.33 ▲ beat |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Financials & Fundamentals (TARS)
| Total Revenue | $606.33M |
|---|---|
| Revenue Growth (YoY) | +69.40% |
| Gross Margin | +82.67% |
| Operating Margin | -11.45% |
| Profit Margin | -7.66% |
| ROE | -13.68% |
| Debt / Equity | 25.61 |
| Current Ratio | 3.2 |
| Total Cash | $449.69M |
| Total Debt | $88.81M |
| Free Cash Flow | $67.47M |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Financial Health Score (TARS)
Nexqual rates Tarsus Pharmaceuticals, Inc.'s overall financial health "Solid" across five dimensions, as of September 8, 2026 at 06:21 UTC.
| Growth | Strong — Revenue +147% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 83%, operating -11% |
| Balance Sheet | Strong — $450M cash vs $89M debt, net cash position |
| Cash Flow | Solid — FCF $67M, 15% margin |
| Efficiency | Critical — ROE -14%, ROA -5.5% |
Ownership (TARS)
| Insider Ownership | +2.86% |
|---|---|
| Institutional Ownership | +106.11% |
| Shares Outstanding | 43.88M |
| Float | 32.70M |
| Short % of Float | +14.12% |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
Leadership (TARS)
Tarsus Pharmaceuticals, Inc. is led by Bobak R. Azamian, Co-Founder, President, CEO & Chairman, per Nexqual as of September 8, 2026 at 06:21 UTC.
| Co-Founder, President, CEO & Chairman | Bobak R. Azamian |
|---|---|
| CFO & Chief Strategy Officer | Jeffrey S. Farrow (age 63) |
| Chief Operating Officer | Seshadri Neervannan (age 57) |
| Vice President of Corporate Communications | Adrienne Kemp |
| Vice President of Marketing | Matthew Rossen (age 47) |
Major Backers & Investors (TARS)
Notable institutional backers of Tarsus Pharmaceuticals, Inc. include Deep Track Capital, Lp, RTW Investments LP, Jupiter Topco LLC, according to Nexqual as of September 8, 2026 at 06:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Deep Track Capital, Lp | 8.36% |
| RTW Investments LP | 7.65% |
| Jupiter Topco LLC | 6.4% |
| Paradigm Biocapital Advisors LP | 6.33% |
| Morgan Stanley | 4.16% |
| Jennison Associates LLC | 3.79% |
| Tang Capital Management, LLC | 3.57% |
| Millennium Management | 3.25% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 12.15% |
| Vanguard Group | 8.08% |
Source: Nexqual, September 8, 2026 at 06:21 UTC.
From Tarsus Pharmaceuticals, Inc.'s Latest SEC 10-K Filing (filed 2026-02-23)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Approach: TP-04 Topical Formulation for Ocular Rosacea There are no FDA-approved therapeutics for ocular rosacea available today.
- Intellectual Property We protect our intellectual property rights and proprietary technology with a combination of patent rights that we own or license in certain fields of use, trademark rights, confidentiality procedures and contractual provisions.
- We seek not only to protect our intellectual property rights and proprietary technology in select key global markets, but also to supplement our intellectual property portfolio with new filings and applications to enhance such protection and support commercialization of current and future product candidates.
- Our continuing research and development activities, technical expertise and contractual arrangements supplement our existing intellectual property protection and help us maintain our competitive position, and we rely on trade secrets to protect our proprietary information and technologies, especially where we do not believe patent protection is appropriate or obtainable, or where such patents would be difficult to enforce.
Partnerships
- In March 2024, we executed an agreement with GrandPharma and LianBio to transition these rights to GrandPharma.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PHAT | Phathom Pharmaceuticals, Inc. | USD 9.5 | ▲ 2.59% |
| STOK | Stoke Therapeutics, Inc. | USD 29.81 | ▼ 2.26% |
| EWTX | Edgewise Therapeutics, Inc. | USD 43.07 | ▲ 2.6% |
| PRAX | Praxis Precision Medicines, Inc | USD 351.81 | ▼ 1.59% |
| INBX | Inhibrx Biosciences, Inc. | USD 121.17 | ▼ 3.04% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:21 UTC. This page is informational and not investment advice.